Literature DB >> 22565623

Use of biosynthetic prosthesis (Omniflow II®) to replace infected infrainguinal prosthetic grafts--first results.

Ingolf Töpel1, Thomas Betz, Christian Uhl, Matthias Wiesner, Stefan Bröckner, Markus Steinbauer.   

Abstract

BACKGROUND: The current treatment standard of infected infrainguinal prosthetic vascular grafts includes total graft explantation and autologous vascular reconstruction. In the absence of appropriate autologous venous graft material prosthetic grafts with increased bacterial resistance can be used, whereas reinfection rates are still higher than after autologous reconstruction. Biosynthetic grafts have shown low postoperative infection rates when used as elective bypass material. Their higher resistance to bacterial infection could make them an alternative to replace infected prosthetic grafts in the absence of autologous material. PATIENTS AND METHODS: Between November 2009 and April 2011, 7 patients with infected infrainguinal prosthetic grafts (Szilagyi 3; 3 supragenicular and 4 infragenicular reconstructions) presented to our institution. There were 4 early (< 3 months after implantation) and 3 late infections (> 3 months after implantation. All grafts were explanted and replaced by biosynthetic grafts (Omniflow II®), because the patient had no suitable peripheral vein for complete autologous replacement. In 2 cases a composite graft with greater saphenous vein was done. In 6 cases microbiological cultures from intraoperatively obtained species were positive. The initial broad spectrum antibiotic therapy was continued according to the antibiogram for 6 to 12 weeks.
RESULTS: There was no early or late reinfection during follow up (mean 9 months, range 4 - 20 months). During follow up we observed graft occlusions in 3 patients (1 due to kinking of the bypass, 1 due to progressive artheriosclerotic occlusion of the outflow vessels and 1 iatrogenic by external compression with a pressure cuff during arthroscopy). There were no early or late major amputations. One patient died with pneumonia 11 months postoperatively.
CONCLUSIONS: In the absence of appropriate autologous material biosynthetic grafts seem to be a possible alternative to replace infected infrainguinal grafts. The different mechanical properties of biosynthetic grafts may be of certain disadvantage in infragenicular reconstructions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565623     DOI: 10.1024/0301-1526/a000188

Source DB:  PubMed          Journal:  Vasa        ISSN: 0301-1526            Impact factor:   1.961


  6 in total

1.  Positive clinical outcomes of the saphenous vein interposition technique for ruptured popliteal artery aneurysm.

Authors:  Isa Coskun; Orhan Saim Demirturk; Huseyin Ali Tunel; Cagatay Andic; Oner Gulcan
Journal:  Surg Today       Date:  2014-03-29       Impact factor: 2.549

2.  [Limb ischemia after total knee arthroplasty].

Authors:  H Dralle; K Kols; T Lesser; A Larena-Avellaneda; M Lainka
Journal:  Chirurg       Date:  2019-03       Impact factor: 0.955

3.  Which prosthesis is more resistant to vascular graft infection: polytetrafluoroethylene or Omniflow II biosynthetic grafts?

Authors:  Orhan Bozoglan; Bulent Mese; Erdinc Eroglu; Serdal Elveren; Mustafa Gul; Ahmet Celik; Halil Ibrahim Yildirimdemir; Harun Ciralik; Alptekin Yasim
Journal:  Surg Today       Date:  2015-03-06       Impact factor: 2.549

4.  Aortic treatment of native infection by reconstruction with the Omniflow II biologic prosthesis.

Authors:  Majid Harmouche; Frederic Loreille; Florent Le Bars; Etienne Marchand; Michel Aupart; Robert Martinez
Journal:  J Vasc Surg Cases Innov Tech       Date:  2018-12-04

5.  Aneurysms and pseudoaneurysms in dialysis access.

Authors:  Anna Mudoni; Marina Cornacchiari; Maurizio Gallieni; Carlo Guastoni; Damian McGrogan; Francesco Logias; Emiliana Ferramosca; Marco Mereghetti; Nicholas Inston
Journal:  Clin Kidney J       Date:  2015-06-10

6.  Xenografts in septic vascular surgery.

Authors:  I Töpel; C Uhl; I Ayx; M Steinbauer
Journal:  Gefasschirurgie       Date:  2016-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.